• Profile

Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: Multicohort, open-label phase 2 KEYNOTE-199 study

Journal of Clinical Oncology Dec 09, 2019

Antonarakis ES, Piulats JM, Gross-Goupil M, et al. - Researchers investigated the antitumor activity and safety of pembrolizumab in three parallel cohorts of a larger metastatic castration-resistant prostate cancer (mCRPC) population. Three cohorts of patients (n = 258) with mCRPC treated with docetaxel and one or more targeted endocrine therapies were assessed in phase 2 KEYNOTE-199 study; 133 in cohort 1, 66 in cohort 2, and 59 in cohort 3. Patients with RECIST-measurable programmed death ligand 1 (PD-L1)–positive and PD-L1–negative disease, respectively, formed cohorts 1 and 2. Patients with bone-predominant disease, regardless of PD-L1 expression formed cohort 3. Outcomes revealed that a subset of patients with RECIST-measurable and bone-predominant mCRPC previously treated with docetaxel and targeted endocrine therapy exhibited antitumor activity in correlation to receiving pembrolizumab monotherapy with an acceptable safety profile of the drug. Witnessed responses appear durable, and overall survival estimates are encouraging.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
  • 55 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Unlimited access to original articles by experts
  • Nonloggedinlock icon
    Secure: we never sell your data
  • Signing up takes less than 2 mins
Try M3 India / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen